Phillip Febbo, MD

@PhilFebboMD_CMO

I am a Physician Scientist and Oncologist at Illumina, Inc as Chief Medical Officer to drive precision medicine and improve patient care through genomic insight

California, USA
Vrijeme pridruživanja: rujan 2013.

Tweetovi

Blokirali ste korisnika/cu @PhilFebboMD_CMO

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @PhilFebboMD_CMO

  1. While pre-analytic variables of diagnostic tests do not grab headlines, they are foundational to valid testing and patient benefit. Proud of this collaboration through bringing academic, industry, and govt together. https://ascpt.onlinelibra...

    Poništi
  2. This study underscores the current under-representation of individuals with non-northern European ancestry and demonstrates the benefit of studying the genetic basis of disease in an African population. Important lessons! ...

    Poništi
  3. 30. sij

    I greatly appreciate the HCPs and disease control experts working to limit the spread and human harm of 2019-nCoV. They are heroes! I am also proud of the Illumina team and tech that are supporting CDCs around the world.

    Poništi
  4. 23. sij

    Thanks and Appreciation for the deep experience and wisdom on learning health systems shared by Lee Newcomer, MD- medical oncologist, past CMO of United Health, and innovator-and Tony Gregg, MD-OBGYN, MFM & genetics expert & physician leader in health systems-at !

    Poništi
  5. 16. sij

    Tragic, sudden deaths of children are devastating to families. While progress is being made, there remains significant work to know who is at risk and prevent. This report highlights how complicated the genetics can be AND shows we are making progress. ...

    Poništi
  6. 13. sij

    Excited to catalyze the ecosystem and accelerate access to oncology-based testing to improve patient outcomes. My thoughts on this partnership, here. “Partnerships Catalyze Patient Access to Genomic Testing "...

    Poništi
  7. 9. sij

    Decreasing the pain and suffering caused by cancer requires continued discovery and implementation of novel testing and therapeutics. However, i...

    Poništi
  8. 9. sij

    Great application of CRISPR to functionally test them impact on cell biology when ultra conserved regions of the genome are altered.

    Poništi
  9. 7. sij

    Great to see bipartisan support for a Federal Bill that extends WGS coverage to a National level. While Project BabyBear has been a great success in CA it is important that the benefits of WGS are available to all children in need

    Poništi
  10. 6. stu 2019.

    A quick reflection on my enthusiasm for liquid biopsies as I head to Baltimore and AMP. Exciting to see better integration of tissue-based and liquid-based biopsies in order to manage cancer patients.

    Poništi
  11. Structural variants (SV) are frequently hidden in the unmapped or soft-clipped genome sequence reads yet they can be genetic drivers of disease. Graph-based approaches are an exciting solution to ID known SVs and improve Dx yield.

    Poništi
  12. While I often lament the slow adoption of diagnostics, this paper reminded me that the practice of medicine can change rapidly. Within 3 years of approval, ~100% of patients with CML were receiving imatinib as outpatients.

    Poništi
  13. An important story of how a boy and his family suffered through an unsuccessful diagnostic odyssey which ended because of a fortunate mistake. We need to ensure children like Alex can reliably and rapidly get to a definitive diagnosis and optimized care.

    Poništi
  14. Primary care providers are the front line of precision medicine but have inadequate training due to the rapid evolution of genetics and the scarcity of their most critical resource-time. Great that is developing CME accred. Genetics 101 modules!

    Poništi
  15. While there is broad support for use of NIPT screening in high risk pregnancies; support is inconsistent for average risk. Dr. McQueen presented real world data showing inc. adoption and decreased inv. procedures when coverage is expanded to average risk

    Poništi
  16. I believe that combining the transcriptome with the genome will provide the most efficient identification & prioritization of variants in genetic disease and onc. This report highlights a recent paper in science that uses allele imbalance for variant ID.

    Poništi
  17. 7. lis 2019.

    With 43 million people living with cancer globally including 18 million people who are diagnosed each year, it is critical that we develop a high quality IVD menu to inform personalized cancer care. Great to partner with QIAGEN to accelerate access

    Poništi
  18. Clinical use of CRISPR with stable engraftment, limited off target impact, but no control of virus when off antiviral Rx. Early example of medicine in a read (sequencing of HLA, HIV, ALL, and Immune cells) AND write (CRISPR) world

    Poništi
  19. As new tech increases our ability to interrogate cancer biology, there has been an ongoing effort to recharacterize cancers as mutation-based rather than organ based. Read my take on pan-cancer biomarkers

    Poništi
  20. It is an honor to join Varian as a Director and help them realize a vision of a world without fear of cancer.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·